Results 221 to 230 of about 5,563,712 (386)

Next‐generation proteomics improves lung cancer risk prediction

Molecular Oncology, EarlyView.
This is one of very few studies that used prediagnostic blood samples from participants of two large population‐based cohorts. We identified, evaluated, and validated an innovative protein marker model that outperformed an established risk prediction model and criteria employed by low‐dose computed tomography in lung cancer screening trials.
Megha Bhardwaj, Clara Frick, Ben Schöttker, Bernd Holleczek, Hermann Brenner   +4 more
wiley   +1 more source

Choosing Less Harmful Alternatives: The Ethics of Harm Reduction in Emerging Technologies. [PDF]

Sci Eng Ethics
Turner C.
europepmc   +1 more source

Intellectual Property Clear inghouses: The Effects of Reduced Transaction Costs in Licensing [PDF]

We focus on downstream uses that combine multiple intellectual property rights and examine the effects of introducing an intellectual property clearinghouse that reduces transaction costs associated with licensing.
Aoki, Reiko, Schiff, Aaron
core  

Harm reduction: A canadian perspective [PDF]

, 2013
Wende Wood
openalex   +1 more source

Anabolics coaching: Emic harm reduction or a public health concern?

Performance Enhancement & Health, 2022
Nicholas Gibbs, L. Cox, Luke A. Turnock
semanticscholar   +1 more source

Potential therapeutic targeting of BKCa channels in glioblastoma treatment

Molecular Oncology, EarlyView.
This review summarizes current insights into the role of BKCa and mitoBKCa channels in glioblastoma biology, their potential classification as oncochannels, and the emerging pharmacological strategies targeting these channels, emphasizing the translational challenges in developing BKCa‐directed therapies for glioblastoma treatment.
Kamila Maliszewska‐Olejniczak, Karolina Pytlak, Sandra Jaworowska, Bogusz Kulawiak, Piotr Bednarczyk   +4 more
wiley   +1 more source

Supervised Injection Facilities as Harm Reduction: A Systematic Review.

American Journal of Preventive Medicine, 2021
Timothy W. Levengood, G. H. Yoon, Melissa Davoust, Shannon N. Ogden, B. Marshall, Sean R. Cahill, A. Bazzi   +6 more
semanticscholar   +1 more source

Effective therapeutic targeting of CTNNB1‐mutant hepatoblastoma with WNTinib

Molecular Oncology, EarlyView.
WNTinib, a Wnt/CTNNB1 inhibitor, was tested in hepatoblastoma (HB) experimental models. It delayed tumor growth and improved survival in CTNNB1‐mutant in vivo models. In organoids, WNTinib outperformed cisplatin and showed enhanced efficacy in combination therapy, supporting its potential as a targeted treatment for CTNNB1‐mutated HB.
Ugne Balaseviciute, Júlia Huguet‐Pradell, Jordi Abril‐Fornaguera, Albert Gris‐Oliver, Alex Rialdi, Elisa Fernández‐Martínez, Carla Montironi, Vanessa Del Pozo, Peter Houghton, Laura Zanatto, Agavni Mesropian, Ieva Keraite, Swan Thung, Carolina Armengol, Pau Sancho‐Bru, Ernesto Guccione, Roser Pinyol, Josep M. Llovet   +17 more
wiley   +1 more source

A no‐brainer for ending AIDS: the case for a harm reduction decade

Journal of the International AIDS Society, 2016
Catherine Cook, Rick Lines, David P Wilson   +2 more
doaj   +1 more source

Harm reduction approaches for the use of benzodiazepines: a scoping review. [PDF]

Harm Reduct J
Morrison C, Natale I, Branchflower A, Harvey C, Lundin RM.   +4 more
europepmc   +1 more source